Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network.

Rafael Amorim Belo Nunes,Precil Diego Miranda de Menezes Neves,Leandro Menezes Alves da Costa,Philip Bachour,Marcelo José de Carvalho Cantarelli,Gustavo Bernardes de Figueiredo Oliveira,Álvaro Avezum

Frontiers in cardiovascular medicine（2023）

引用 0|浏览4

暂无评分

摘要

In this retrospective study with a large number of patients with CML, those treated with nilotinib had a higher 5-year ratio of ACE, while patients with dasatinib showed a lower ratio than patients with imatinib. The ratio of heart failure was higher in patients with imatinib than in patients with dasatinib, but not when compared to nilotinib.

查看译文

关键词

breakpoint cluster region-abelson (BCR-ABL),cardio-onco-hematology,cardiovascular safety,chronic myeloid leukemia,tyrosine kinase inhibitor (TKI)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要